Komori
Immuno-Biological Laboratories (4570) · TargetWorsened

Full-year profit generation from the cosmetics-related business

First written in FY2018-Q1. 15 of 33 entries say "Worsened", first in FY2019. Latest entry: 2026-08-07.

33entries
10years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseWorsenedFY2019 – FY2021-Q12017: 220172018: 320182019: 420192020: 420202021: 420212022: 220222023: 420232024: 320242025: 220252026: 52026
Same theme, other companies
Full-year profit generation from the cosmetics-related businessA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. 2026-08-07WorsenedEarnings

    「The cosmetics-related business reported revenue of ¥536 thousand, down 19.5% year on year, as sales to domestic mail-order distributors declined. As a result, the business recorded an operating loss of ¥398 thousand due to lower revenue.」

    The cosmetics-related business, which had returned to full-year profitability in the previous fiscal year, reported lower revenue and an operating loss in the first quarter.
  2. FY2026WorsenedAnnual report

    「The business sells cosmetics mainly through domestic mail-order channels. However, because sufficient promotional activities, including advertising, could not be conducted, revenue was ¥2.679 million, down 48.1% year on year, and the business recorded an operating loss of ¥609 thousand, compared with operating income of ¥1.164 million in the previous year.」

    The cosmetics-related business achieved full-year operating profitability in the previous fiscal year, but recorded an operating loss of ¥0.609 million in the current fiscal year due to insufficient promotional activity, representing a setback in full-year profit generation.
  3. FY2026-H1WorsenedAnnual report

    「Revenue in this business during the interim consolidated accounting period was centered on domestic mail-order sales but declined 53.5% year on year to ¥1.384 million because sales to distributors decreased. Operating results also deteriorated, resulting in an operating loss of ¥322,000, compared with operating profit of ¥723,000 in the same period of the previous year.」

    The cosmetics-related business recorded a first-half operating loss of ¥0.322 million, deteriorating from operating income of ¥0.723 million in the same period of the previous year. Whether the full-year profit-generation target will be achieved cannot be determined solely from the results for the current six-month consolidated accounting period.
  4. FY2025AchievedAnnual report

    「Operating income was ¥1.164 million, compared with an operating loss of ¥3.516 million in the same period of the previous year, because advertising expenses were reduced.」

    The cosmetics-related business recorded full-year operating income of ¥1.164 million by containing advertising expenses, turning profitable from the operating loss recorded in the previous year. It achieved its full-year profit-generation target in actual results.
  5. FY2025-H1AdvancedAnnual report

    「Revenue for the business during the first six months of the current consolidated fiscal period increased 41.3% year on year to ¥2.977 million, mainly because sales through domestic mail order increased sales to distributors. Operating income was ¥0.723 million, compared with an operating loss of ¥3.079 million in the same period of the previous year.」

    The cosmetics-related business turned to operating income of ¥0.723 million in the first half as sales to distributors increased. However, this does not state that full-year profit generation or profitability was achieved.
  6. FY2024Loss narrowed, but full-year profitability not achievedAnnual report

    「Revenue in the cosmetics-related business, which is centered on domestic mail-order sales, declined from the previous year to ¥3.851 million, down 4.2% year on year, because promotional activities were insufficient due to a labor shortage. By containing selling expenses, including through the closure of the Takasaki shop, the business recorded an operating loss of ¥3.516 million, compared with an operating loss of ¥13.344 million in the same period of the previous year, representing an improvement.」

    The operating loss narrowed from ¥13.344 million to ¥3.516 million through the containment of selling expenses, but the business did not generate a full-year profit or turn profitable.
  7. FY2024-Q3AdvancedAnnual report

    「Revenue for the business was ¥3.045 million, broadly in line with the previous year and up 3.2% year on year, with domestic mail-order sales accounting for most of it. By containing selling, general and administrative expenses, the business recorded an operating loss of ¥3.546 million, compared with an operating loss of ¥11.472 million in the same period of the previous year, representing an improvement.」

    The cosmetics-related business generated revenue of ¥3.045 million, up 3.2% year on year, while its operating loss narrowed from ¥11.472 million in the same period of the previous year to ¥3.546 million through the containment of selling, general and administrative expenses. However, it had not yet turned profitable.
  8. FY2024-Q2AdvancedAnnual report

    「Revenue for the business was ¥2.106 million, broadly in line with the previous year and up 6.0% year on year, with domestic mail-order sales accounting for most of it. By containing selling expenses, the business recorded an operating loss of ¥3.079 million, compared with an operating loss of ¥8.024 million in the same period of the previous year, representing an improvement.」

    The cosmetics-related business increased revenue 6.0% year on year, while its operating loss narrowed from ¥8.024 million in the same period of the previous year to ¥3.079 million through the containment of selling expenses. However, it had not yet begun generating a full-year profit.
  9. FY2024-Q1MitigatedAnnual report

    「Cosmetics-related business ¥0.822 million -¥0.006 million -0.8% -¥2.295 million +¥2.512 million -」

    The cosmetics-related business generated revenue of ¥0.822 million and recorded an operating loss of ¥2.295 million. Revenue was almost flat year on year, while the operating loss narrowed from ¥4.807 million. However, the business had not yet begun generating a full-year profit.
  10. FY2023WorsenedAnnual report

    「As a result, revenue was ¥4.021 million, down 69.9% year on year, and the operating loss was ¥13.344 million, compared with an operating loss of ¥12.565 million in the same period of the previous year.」

    Although the cosmetics-related business advanced measures including cross-border e-commerce in China, revenue declined 69.9% year on year to ¥4.021 million, and it recorded an operating loss of ¥13.344 million, so it did not achieve its full-year profit-generation target.
  11. FY2023-Q3WorsenedAnnual report

    「To clarify the sales strategy and target for domestic mail-order sales, the business has switched from selling directly to individual users to selling through distributors. As a result, revenue has declined because the wholesale unit price to distributors was reduced, but expenses related to domestic mail-order sales were substantially contained. The business also established cross-border e-commerce operations for China and has begun sales, but the response in mainland China has been limited and the impact on revenue has been minor.」

    Progress was made in switching to distributor sales, containing domestic expenses and launching cross-border e-commerce in China, but revenue was ¥2.952 million, down 74.8% year on year, and the operating loss was ¥11.472 million.
  12. FY2023-Q2WorsenedAnnual report

    「To clarify the sales strategy and target for domestic mail-order sales, the business has switched from selling directly to individual users to selling through distributors. As a result, revenue has declined because the wholesale unit price to distributors was reduced, but expenses related to domestic mail-order sales were substantially contained. The business also established cross-border e-commerce operations for China and began sales in late June, but the response in mainland China has been limited and the impact on revenue has been minor.」

    Although progress was made in switching to distributor sales, containing domestic sales expenses and launching cross-border e-commerce in China, the cosmetics-related business generated revenue of ¥1.986 million, down 80.0% year on year, and recorded an operating loss of ¥8.024 million due to the lower wholesale unit price and limited response in mainland China.
  13. FY2023-Q1WorsenedAnnual report

    「For domestic mail-order sales, the company switched from selling directly to individual users to selling through distributors. As a result, revenue declined because the wholesale unit price to distributors was reduced, but it was able to substantially contain expenses related to domestic mail-order sales. It also established cross-border e-commerce operations for China, with sales beginning in late June. Cosmetics-related business ¥0.829 million -¥1.046 million -55.8% -¥4.807 million -¥1.010 million -」

    Although progress was made in switching to distributor sales and launching cross-border e-commerce in China, the cosmetics-related business generated revenue of ¥0.829 million, down 55.8% year on year, and recorded an operating loss of ¥4.807 million, so the full-year profit-generation target remains unmet.
  14. FY2022-Q2First-half loss narrowed, but full-year profitability not achievedAnnual report

    「Cosmetics-related business ¥9.931 million +¥6.640 million 201.8% -¥5.033 million +¥4.892 million -」

    The cosmetics-related business generated first-half revenue of ¥9.931 million and recorded an operating loss of ¥5.033 million. Although the loss narrowed from the same period of the previous year, the full-year profit-generation target was not achieved.
  15. FY2022-Q1AdvancedAnnual report

    「As a result, the segment generated revenue of ¥1.875 million, up 5.5% year on year, and recorded an operating loss of ¥3.796 million, compared with an operating loss of ¥5.695 million in the same period of the previous year.」

    The cosmetics-related business saw revenue increase 5.5% year on year, while its operating loss narrowed from ¥5.695 million to ¥3.796 million. It has not yet begun generating a full-year profit.
  16. FY2021MitigatedAnnual report

    「As a result, the segment generated revenue of ¥14.146 million, up 9.9% year on year, and recorded an operating loss of ¥13.820 million, compared with an operating loss of ¥53.741 million in the same period of the previous year.」

    The cosmetics-related business did not generate a full-year profit, but revenue increased 9.9% and the operating loss narrowed from ¥53.741 million to ¥13.820 million.
  17. FY2021-Q3Operating loss narrowed, but losses continuedAnnual report

    「As a result, the segment generated revenue of ¥5.021 million, down 28.7% year on year, and recorded an operating loss of ¥13.854 million, compared with an operating loss of ¥16.345 million in the same period of the previous year.」

    The cosmetics-related business saw revenue decline 28.7% year on year, while its operating loss narrowed from ¥16.345 million to ¥13.854 million. It has not yet begun generating a full-year profit.
  18. FY2021-Q2Operating loss narrowed, but losses continuedAnnual report

    「As a result, the segment generated revenue of ¥3.290 million, down 26.7% year on year, and recorded an operating loss of ¥9.925 million, compared with an operating loss of ¥12.788 million in the same period of the previous year.」

    The cosmetics-related business saw revenue decline 26.7% year on year, while its operating loss narrowed from ¥12.788 million to ¥9.925 million. Progress has been made toward beginning sales in Europe, but the business remains in the red.
  19. FY2021-Q1WorsenedAnnual report

    「As a result, the segment generated revenue of ¥1.777 million, down 11.1% year on year, and recorded an operating loss of ¥5.695 million, compared with an operating loss of ¥4.724 million in the same period of the previous year.」

    The cosmetics-related business saw revenue decline 11.1% year on year, while its operating loss widened from ¥4.724 million to ¥5.695 million. The Chinese trademark issue continues, while the European sales website has been completed.
  20. FY2020WorsenedAnnual report

    「As a result, the segment generated revenue of ¥12.873 million, compared with ¥153.000 million in the medium-term plan, down 69.9% year on year. The medium-term plan called for operating income of ¥52.000 million, but the segment recorded an operating loss of ¥53.741 million, partly because the company conservatively recognized an impairment loss on products intended for sale in China after determining that the timing of shipments to China could not be established.」

    The cosmetics-related business recorded an operating loss of ¥53.741 million against the ¥52.000 million operating income projected in the medium-term plan and failed to meet its full-year profit-generation target.
  21. FY2020-Q3WorsenedAnnual report

    「As a result, the segment generated revenue of ¥7.042 million, down 82.4% year on year, and recorded an operating loss of ¥16.345 million, compared with operating income of ¥0.322 million in the same period of the previous year.」

    Sales to China have not resumed, and the cosmetics-related business saw revenue decline 82.4% year on year, swinging from operating income of ¥0.322 million in the same period of the previous year to an operating loss of ¥16.345 million. Preparations are under way for European sales to begin in the fourth quarter.
  22. FY2020-Q2WorsenedAnnual report

    「As a result, the segment generated revenue of ¥4.491 million, down 87.9% year on year, and recorded an operating loss of ¥12.788 million, compared with operating income of ¥8.231 million in the same period of the previous year.」

    Sales to China have not fully resumed, and the cosmetics-related business generated revenue of ¥4.491 million, down 87.9% year on year, and recorded an operating loss of ¥12.788 million. It swung into the red from operating income of ¥8.231 million in the same period of the previous year.
  23. FY2020-Q1WorsenedAnnual report

    「As a result, the segment generated revenue of ¥1.998 million, down 1.7% year on year, and recorded an operating loss of ¥4.724 million, compared with an operating loss of ¥2.729 million in the same period of the previous year.」

    The cosmetics-related business saw revenue decline 1.7% year on year, while its operating loss widened from ¥2.729 million in the same period of the previous year to ¥4.724 million. The business recorded a loss in the quarter against its full-year profit-generation target.
  24. FY2019WorsenedAnnual report

    「As a result, the segment generated revenue of ¥42.803 million, up 101.3% year on year, and recorded an operating loss of ¥6.654 million, compared with an operating loss of ¥8.651 million in the same period of the previous year.」

    Revenue increased 101.3% year on year due partly to the start of sales to China, but the business recorded a full-year operating loss of ¥6.654 million and did not achieve the cosmetics-related business’s full-year profit-generation target.
  25. FY2019-Q3Profit generation continued, but shipments to China were delayedAnnual report

    「Domestic mail-order sales of the Frevan series of cosmetics containing Neo Silk® human-type collagen I declined, but sales to China began following approval for sale there, increasing revenue. However, during the third quarter accounting period, shipments to China are scheduled to be delayed until the fourth quarter accounting period or later because the company is discussing the impact of product delivery and other matters, as well as the handling of intellectual property rights, with its Chinese sales distributor. As a result, the segment generated revenue of ¥40.058 million, up 196.7% year on year, and recorded operating income of ¥0.322 million, compared with an operating loss of ¥7.703 million in the same period of the previous year. The business was able to record a profit. The business aims to generate a profit for the full year.」

    Revenue increased following the start of sales to China, and the business recorded operating income of ¥0.322 million, while shipments to China are scheduled to be delayed until the fourth quarter or later. The full-year profit-generation target remains in place.
  26. FY2019-Q2AdvancedAnnual report

    「In this business, domestic mail-order sales of the Frevan series of cosmetics containing Neo Silk® human-type collagen I declined, but sales to China began after the products were approved for sale there. As announced in the medium-term management plan, the company expects sales to expand substantially going forward. As a result, the segment generated revenue of ¥37.122 million, up 414.8% year on year, and recorded operating income of ¥8.231 million, compared with an operating loss of ¥4.810 million in the same period of the previous year. This was the first time the business had recorded a profit. The business aims to generate a profit for the full year.」

    The business made concrete progress by beginning sales to China and recording its first-ever profit in the cosmetics-related business. Revenue increased 414.8% year on year and operating income was ¥8.231 million, but full-year profit generation remains a target.
  27. FY2019-Q1AdvancedAnnual report

    「Going forward, sales of the Frevan series of cosmetics containing Neo Silk® human-type collagen I in China have been approved, and sales to China will finally begin in the second quarter.」

    There was concrete progress toward the cosmetics-related business’s profit-generation target, with approval obtained for sales to China and sales scheduled to begin in the second quarter. However, the business recorded an operating loss of ¥2.729 million in the first quarter.
  28. FY2018-Q3SoftenedAnnual report

    「The business had aimed to generate a profit for the full year, but because the application for sales to China was pushed back to the next fiscal year, it will aim to turn profitable in the next fiscal year.」

    The target of turning the cosmetics-related business profitable in the current fiscal year was pushed back to the next fiscal year because the application for sales to China was delayed until then.
  29. FY2018-Q2AdvancedAnnual report

    「As a result, the segment generated revenue of ¥7.210 million, up 35.6% year on year, and recorded an operating loss of ¥4.810 million, compared with an operating loss of ¥8.899 million in the same period of the previous year. The business aims to turn profitable for the full year.」

    The cosmetics-related business increased revenue 35.6% year on year, while its operating loss narrowed from ¥8.899 million to ¥4.810 million. Although the figures improved toward the full-year profitability target, the business did not achieve full-year profitability.
  30. FY2018-Q1First statedAnnual report

    「In this business, we aim to generate a profit for the full year.」

    For the cosmetics-related business, which is advancing sales to Southeast Asia, preparations for sales to China and preparations for sales with European distributors, the company explicitly stated for the first time that generating a full-year profit was its objective.
Moved together

"Expansion of lipid analysis services based on LipoSEARCH" moved the same way as this thread, in the same document, in 20 of its 33 moves.

201414111111★123456
  1. ★This thread
  2. 1Expansion of lipid analysis services based on LipoSEARCH20×
  3. 2Expansion of sales channels for Neo Silk human collagen cosmetics14×
  4. 3Full-Year Profit Generation in the Testing Business14×
  5. 4Improving Profitability Through a Change in the Sales Policy for the Diagnostics and Reagents Business11×
  6. 5Narrowing Operating Losses and Continued Losses11×
  7. 6Risk of losses and deterioration in operating cash flow associated with strengthening basic research11×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet. It last moved in the Earnings of 2026-08-07: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Full-year profit generation from the cosmetics-related business | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori